Table 2.
N-glycosylation site occupancy of three CD16a variants (n.a. - not applicable, *- lower bound due to peak overlap, ** - no N peak observed, *** - lower bound due to supplemental 18O incorporation).
|
16O-water |
18O-water |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| CD16a variant: |
V158 |
F158 |
T171A |
YTS |
V158 |
F158 |
T171A |
YTS |
|
| Native Peptide | site - peptide # | % | % | % | % | % | % | % | % |
| DNSTQWF | N38-1 | 91 ± 14 | |||||||
| SPEDNSTQW | N38-2 | ≥92.5 * | |||||||
| KCQGAYSPEDNSTQW | N38-4 | ≥60 * | 80 ± 22 | 100 ** | |||||
| STQWFHNE | N45-1 | 98 ± 11 | 95.8 ± 1.7 | >98.9 *** | |||||
| FHNE | N45-2 | 81 ± 28 | |||||||
| FHNESLISSQASSY | N45-4 | 92 ± 14 | 99.8 ± 8.9 | 96 ± 12 | |||||
| RCQTNLSTL | N74-1 | 92.8 ± 2.0 | 94.6 ± 2.5 | 97.3 ± 9.3 | >96.3 *** | 100 *** | >98.9 *** | 100 ± 9 | |
| RCQTNLSTLSDPVQLE | N74-2 | 89.4 ± 0.9 | 98.8 ± 2.0 | 98.4 ± 3.2 | >98.0 *** | >99.8 *** | |||
| VGSKNVSSE | N162-1 | NA | 96 ± 18 | ||||||
| GLVGSKNVSSE | N162-2 | 79.6 ± 2.2 | NA | 99.6 ± 2.8 | >67.2 *** | >99.8 *** | |||
| CRGLVGSKNVSSE | N162-3 | 70 ± 15 | NA | >64.9 *** | |||||
| (F158) FGSKNVSSE (only) | N162-4 | NA | 98.9 ± 4.8 | NA | NA | NA | >99 *** | NA | |
| TVNITITQG | N169-1 | 88.0 ± 1.1 | 99.6 ± 1.6 | NA | 100 ± 22 | >84.9 *** | 100 *** | NA | 93 ± 10 |
| TVNIAITQG (T171A only) | N169-2 | NA | NA | 0.0 ± 1.2 | NA | NA | NA | 0.0 ± 2.2 | |